<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02171988</url>
  </required_header>
  <id_info>
    <org_study_id>1401091550</org_study_id>
    <nct_id>NCT02171988</nct_id>
  </id_info>
  <brief_title>Effect of Medical Treatment and Prognosis of Postural Orthostatic Tachycardia Syndrome (POTS)</brief_title>
  <acronym>POTS</acronym>
  <official_title>Comparison of Effect of Propranolol, Bisoprolol, Pyridosgitmine in Postural Orthostatic Tachycardia Syndrome (POTS) and Prognosis After Medical Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to investigate effect of medical treatment and prognosis of
      Postural Orthostatic Tachycardia Syndrome (POTS)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Many patients who complained of dizziness are eventually diagnosed as POTS. However, the
      investigation of an appropriate medical treatment of POTS has not been enough yet. Also, the
      prognosis of the disease after treatment is not well known. It is known that propranolol
      attenuate the tachycardia and improve symptom burden in patients with POTS. However, the
      effect of other β-Blocker, bisoprolol compared with propranolol is not known well. In
      addition, acetylcholinesterase inhibition with pyridostigmine was a effective method of
      acutely decreasing the tachycardia in patients with POTS. However, difference among three
      medical treatments effect is not known and long-term studies are not done yet. Therefore, in
      this study investigator investigate effect of medical treatment (propranolol only, bisoprolol
      only, propranolol+pyridostigmine, bisoprolol+pyridostigmine) and prognosis of Postural
      Orthostatic Tachycardia Syndrome.

      Longer-term studies are needed to assess this promising therapy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change of the subjective symptom survey result after 3-month medical treatment.</measure>
    <time_frame>3 month after medical treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Normalization of orthostatic BP-HR test after 6-month medical treatment.</measure>
    <time_frame>6 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of the subjective symptom after 6-month medical treatment.</measure>
    <time_frame>6 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of quality of life score after treatment</measure>
    <time_frame>6 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of depression score after treatment</measure>
    <time_frame>6 month</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Postural Orthostatic Tachycardia Syndrome</condition>
  <arm_group>
    <arm_group_label>Propranolol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Start propranolol 10mg bid, and then dose up to 20mg bid after one month if tolerable</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bisoprolol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Start bisoprolol 2.5mg qd P.O, and then dose up to 5mg qd. if tolerable</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Propranolol+pyridostigmine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Start propranolol+pyridostigmine 10mg bid +30mg bid, and then dose up to 20mg bid+30mg bid. if tolerable.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bisoprolol+pyridostgmine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>start bisoprolol+pyridostgmine 2.5mg qd+30mg bid, and then, dose up to 5mg qd+30mg bid. if tolerable</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propranolol</intervention_name>
    <description>Start propranolol 10mg bid, and then dose up to 20mg bid after one month if tolerable</description>
    <arm_group_label>Propranolol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bisoprolol</intervention_name>
    <description>Start bisoprolol 2.5mg qd P.O, and then dose up to 5mg qd. if tolerable</description>
    <arm_group_label>Bisoprolol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propranolol+pyridostigmine</intervention_name>
    <description>Start propranolol+pyridostigmine 10mg bid +30mg bid, and then dose up to 20mg bid+30mg bid. if tolerable.</description>
    <arm_group_label>Propranolol+pyridostigmine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bisoprolol+pyridostgmine</intervention_name>
    <description>Start bisoprolol+pyridostgmine 2.5mg qd+30mg bid, and then, dose up to 5mg qd+30mg bid. if tolerable</description>
    <arm_group_label>Bisoprolol+pyridostgmine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  aged 15&lt;=

          -  developed symptoms of orthostatic intolerance accompanied by a HR rise ≥30 min−1
             within the first 10 minutes of standing, HR rise ≥ 120 in the absence of orthostatic
             hypotension (a fall in blood pressure [BP] &gt;20/10 mm Hg).

        Exclusion Criteria:

          -  poor drug compliance

          -  patients who cannot or do not want to write questionaires.

          -  patients who do not want draw blood
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kon Chu, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Raj SR, Black BK, Biaggioni I, Harris PA, Robertson D. Acetylcholinesterase inhibition improves tachycardia in postural tachycardia syndrome. Circulation. 2005 May 31;111(21):2734-40. Epub 2005 May 23.</citation>
    <PMID>15911704</PMID>
  </reference>
  <reference>
    <citation>Raj SR, Black BK, Biaggioni I, Paranjape SY, Ramirez M, Dupont WD, Robertson D. Propranolol decreases tachycardia and improves symptoms in the postural tachycardia syndrome: less is more. Circulation. 2009 Sep 1;120(9):725-34. doi: 10.1161/CIRCULATIONAHA.108.846501. Epub 2009 Aug 17.</citation>
    <PMID>19687359</PMID>
  </reference>
  <reference>
    <citation>Fu Q, Vangundy TB, Shibata S, Auchus RJ, Williams GH, Levine BD. Exercise training versus propranolol in the treatment of the postural orthostatic tachycardia syndrome. Hypertension. 2011 Aug;58(2):167-75. doi: 10.1161/HYPERTENSIONAHA.111.172262. Epub 2011 Jun 20.</citation>
    <PMID>21690484</PMID>
  </reference>
  <reference>
    <citation>Kimpinski K, Figueroa JJ, Singer W, Sletten DM, Iodice V, Sandroni P, Fischer PR, Opfer-Gehrking TL, Gehrking JA, Low PA. A prospective, 1-year follow-up study of postural tachycardia syndrome. Mayo Clin Proc. 2012 Aug;87(8):746-52. doi: 10.1016/j.mayocp.2012.02.020. Epub 2012 Jul 15.</citation>
    <PMID>22795533</PMID>
  </reference>
  <reference>
    <citation>Sousa A, Lebreiro A, Freitas J, Maciel MJ. Long-term follow-up of patients with postural tachycardia syndrome. Clin Auton Res. 2012 Jun;22(3):151-3. doi: 10.1007/s10286-011-0155-1. Epub 2011 Dec 22.</citation>
    <PMID>22190289</PMID>
  </reference>
  <reference>
    <citation>Winker R, Barth A, Bidmon D, Ponocny I, Weber M, Mayr O, Robertson D, Diedrich A, Maier R, Pilger A, Haber P, Rüdiger HW. Endurance exercise training in orthostatic intolerance: a randomized, controlled trial. Hypertension. 2005 Mar;45(3):391-8. Epub 2005 Feb 7.</citation>
    <PMID>15699447</PMID>
  </reference>
  <reference>
    <citation>Arnold AC, Okamoto LE, Diedrich A, Paranjape SY, Raj SR, Biaggioni I, Gamboa A. Low-dose propranolol and exercise capacity in postural tachycardia syndrome: a randomized study. Neurology. 2013 May 21;80(21):1927-33. doi: 10.1212/WNL.0b013e318293e310. Epub 2013 Apr 24.</citation>
    <PMID>23616163</PMID>
  </reference>
  <reference>
    <citation>Benarroch EE. Postural tachycardia syndrome: a heterogeneous and multifactorial disorder. Mayo Clin Proc. 2012 Dec;87(12):1214-25. doi: 10.1016/j.mayocp.2012.08.013. Epub 2012 Nov 1. Review.</citation>
    <PMID>23122672</PMID>
  </reference>
  <reference>
    <citation>Mathias CJ, Low DA, Iodice V, Owens AP, Kirbis M, Grahame R. Postural tachycardia syndrome--current experience and concepts. Nat Rev Neurol. 2011 Dec 6;8(1):22-34. doi: 10.1038/nrneurol.2011.187. Review.</citation>
    <PMID>22143364</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 19, 2014</study_first_submitted>
  <study_first_submitted_qc>June 22, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2014</study_first_posted>
  <last_update_submitted>April 16, 2018</last_update_submitted>
  <last_update_submitted_qc>April 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Kon Chu</investigator_full_name>
    <investigator_title>MD, PhD, professor</investigator_title>
  </responsible_party>
  <keyword>Postural Orthostatic Tachycardia Syndrome</keyword>
  <keyword>propranolol</keyword>
  <keyword>bisoprolol</keyword>
  <keyword>pyridostigmine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Postural Orthostatic Tachycardia Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propranolol</mesh_term>
    <mesh_term>Bisoprolol</mesh_term>
    <mesh_term>Pyridostigmine Bromide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

